Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

被引：0
|
作者：
Martin Fenner
Christoph Oing
Annette Dieing
Thomas Gauler
Karin Oechsle
Anja Lorch
Marcus Hentrich
Hans-Georg Kopp
Carsten Bokemeyer
Friedemann Honecker
机构：
[1] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
[2] University Medical Center Hamburg-Eppendorf,Department of Oncology, Hematology and Bone Marrow Transplantation and Section of Pneumology
[3] Vivantes Hospital am Urban,Department of Hematology and Oncology
[4] Heinrich Heine University Medical Center Essen,Department of Radiotherapy and Radiation Oncology
[5] University Medical Center Duesseldorf,Genitourinary Medical Oncology, Department of Urology
[6] Red Cross Hospital Munich,Department of Internal Medicine III, Hematology and Oncology
[7] University Medical Center Tuebingen,Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology
[8] Robert-Bosch-Centrum für Tumorerkrankungen,Department of Molecular Oncology and Pneumological Oncology
[9] Robert-Bosch Hospital,undefined
[10] ZeTuP Tumor and Breast Center,undefined
[11] DataCite,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Germ cell cancer; Testicular cancer; mTOR; Everolimus; Refractory; Cisplatin resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：717 / 723
页数：6
相关论文
共 50 条
  • [1] Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
    Fenner, Martin
    Oing, Christoph
    Dieing, Annette
    Gauler, Thomas
    Oechsle, Karin
    Lorch, Anja
    Hentrich, Marcus
    Kopp, Hans-Georg
    Bokemeyer, Carsten
    Honecker, Friedemann
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (03) : 717 - 723
  • [2] A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer(RADIT)
    Fenner, Martin H.
    Dieing, Annetta
    Oechsle, Karin
    Hentrich, Marcus
    Gauler, Thomas Christoph
    Lorch, Anja
    Kopp, Hans-Georg
    Beyer, Joerg
    Bokemeyer, Carsten
    Gruenwald, Viktor
    Honecker, Friedmann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
  • [4] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
  • [5] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [6] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    Powles, T
    Shamash, J
    Berney, D
    Oliver, RTD
    BRITISH JOURNAL OF CANCER, 2003, 89 (06) : 1140 - 1141
  • [7] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    T Powles
    J Shamash
    D Berney
    R T D Oliver
    British Journal of Cancer, 2003, 89 : 1140 - 1141
  • [8] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    O Rick
    H Klaproth
    T Kubin
    H G Sayer
    M Hentrich
    M Welslau
    F Mayer
    M Kuczyk
    C Spott
    L Kanz
    C Bokemeyer
    British Journal of Cancer, 2002, 87 : 729 - 732
  • [9] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    Kollmannsberger, C
    Rick, O
    Klaproth, H
    Kubin, T
    Sayer, HG
    Hentrich, M
    Welslau, M
    Mayer, F
    Kuczyk, M
    Spott, C
    Kanz, L
    Bokemeyer, C
    BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 729 - 732
  • [10] Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial
    Liu, Yanyan
    Lin, Ningjing
    Yi, Shuhua
    Huang, Huiqiang
    Guo, Ye
    Zhang, Qingyuan
    Yang, Haiyan
    Zhang, Huilai
    Zhang, Liling
    Feng, Ru
    Qian, Yijiao
    Zhu, Jiankun
    Song, Yuqin
    Zhu, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2025,
12345